Glipizid LPH

Glipizid LPH may be available in the countries listed below.

Ingredient matches for Glipizid LPH

Glipizide

Glipizide is reported as an ingredient of Glipizid LPH in the following countries:

• Romania

International Drug Name Search

Bromodel

Bromodel may be available in the countries listed below.

Ingredient matches for Bromodel

Bromocriptine

Bromocriptine mesilate (a derivative of Bromocriptine) is reported as an ingredient of Bromodel in the following countries:

• Bangladesh

International Drug Name Search

Nidazole

Nidazole may be available in the countries listed below.

Ingredient matches for Nidazole

Metronidazole

Metronidazole is reported as an ingredient of Nidazole in the following countries:

• Bahrain


• Indonesia


• Iraq


• Jordan


• Oman


• Saudi Arabia


• Syria


• United Arab Emirates


• Yemen

International Drug Name Search

Colchicine-Odan

Colchicine-Odan may be available in the countries listed below.

Ingredient matches for Colchicine-Odan

Colchicine

Colchicine is reported as an ingredient of Colchicine-Odan in the following countries:

• Canada

International Drug Name Search

Nodescrón

Nodescrón may be available in the countries listed below.

Ingredient matches for Nodescrón

Vecuronium

Vecuronium Bromide is reported as an ingredient of Nodescrón in the following countries:

• Mexico

International Drug Name Search

Avandamet

Avandamet is a brand name of metformin/rosiglitazone, approved by the FDA in the following formulation(s):

AVANDAMET (metformin hydrochloride; rosiglitazone maleate - tablet; oral)

• 
  Manufacturer: SB PHARMCO
  
  Approval date: October 10, 2002
  
  Strength(s): 500MG;EQ 2MG BASE, 500MG;EQ 4MG BASE
  


• 
  Manufacturer: SB PHARMCO
  
  Approval date: August 25, 2003
  
  Strength(s): 1GM;EQ 2MG BASE, 1GM;EQ 4MG BASE ^[RLD]

Has a generic version of Avandamet been approved?

No. There is currently no therapeutically equivalent version of Avandamet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avandamet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Novel compounds
  Patent 5,002,953
  Issued: March 26, 1991
  Inventor(s): Hindley; Richard M.
  Assignee(s): Beecham Group p.l.c.
  Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
  
  Patent expiration dates:
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 17, 2011
    
    ✓ 
    Patent use: USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 17, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Substituted thiazolidinedionle derivatives
  Patent 5,741,803
  Issued: April 21, 1998
  Inventor(s): Pool; Colin Ripley & Tremper; Alan William & Brightwell; Malcolm David & Roman; Robin Sherwood
  Assignee(s): SmithKline Beecham plc
  ##STR1## A compound of formula (I) or a tautomeric form therof and/or a pharmaceutically acceptable solvate thereof, wherein R1,A1,A2,M are as defined in the, specification. A process for preparing such a compound, a pharmaceutical composition containin such a compound and the use of such a compound for treating hyperglycemia.
  
  Patent expiration dates:
  
  
  • April 21, 2015
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • April 21, 2015
    
    ✓ 
    Patent use: FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • October 21, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition
  Patent 5,965,584
  Issued: October 12, 1999
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Pharmaceutical composition
  Patent 6,166,042
  Issued: December 26, 2000
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Compounds
  Patent 6,288,095
  Issued: September 11, 2001
  Inventor(s): Hindley; Richard Mark & Cawthorne; Michael Antony
  Assignee(s): Beecham Group p.l.c.
  A method is provided for the treatment and/or prophylaxis of cardiovascular diseases or eating disorders in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## or a tautomeric form thereof and/or a pharmaceuticlaly acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in which A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6.
  
  Patent expiration dates:
  
  
  • February 11, 2017
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • August 11, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Thiazolidinedione derivative and its use as antidiabetic
  Patent 7,358,366
  Issued: April 15, 2008
  Inventor(s): Blackler; Paul David James & Giles; Robert Gordon & Moore; Stephen & Sasse; Michael John
  Assignee(s): SmithKline Beecham p.l.c.
  A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
  
  Patent expiration dates:
  
  
  • April 19, 2020
    
    ✓ 
    Drug substance
  
  
  
  • October 19, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Avandamet Consumer Information (Drugs.com)
• Avandamet Consumer Information (Wolters Kluwer)
• Avandamet Consumer Information (Cerner Multum)
• Avandamet Advanced Consumer Information (Micromedex)
• Rosiglitazone/Metformin Consumer Information (Wolters Kluwer)
• Metformin and rosiglitazone Consumer Information (Cerner Multum)
• Metformin and rosiglitazone Advanced Consumer Information (Micromedex)
• Rosiglitazone and metformin Advanced Consumer Information (Micromedex)